-transparent.png){kind=logo}
Omeprazole and other substituted benzimidazoles produce a marked inhibition of gastric acid secretion with a long duration of action. Any kind of stimulated acid secretion is inhibited by the substituted benzimidazoles. The inhibitory mechanism of action is very selective. The substituted benzimidazoles inhibit the parietal cell H+, K+-ATPase, an enzyme which is the proton pump in the secretory membrane of the parietal cell. An oral daily dose of 15 mg omeprazole in humans produced about 80% acid inhibition just after dosage and about 40% 24 hours later. Preliminary results in duodenal ulcer patients show that a daily dose of 20-60 mg omeprazole produces fast ulcer healing in almost all patients.
L Olbe, and
T Lind, and
E Carlsson, and
C Cederberg, and
H Helander, and
B Wallmark
February 1982,
Fortschritte der Medizin,
L Olbe, and
T Lind, and
E Carlsson, and
C Cederberg, and
H Helander, and
B Wallmark
April 1989,
Arzneimittel-Forschung,
L Olbe, and
T Lind, and
E Carlsson, and
C Cederberg, and
H Helander, and
B Wallmark
July 1978,
Die Medizinische Welt,
L Olbe, and
T Lind, and
E Carlsson, and
C Cederberg, and
H Helander, and
B Wallmark
December 1982,
The American journal of physiology,
L Olbe, and
T Lind, and
E Carlsson, and
C Cederberg, and
H Helander, and
B Wallmark
January 1976,
Proceedings of the National Academy of Sciences of the United States of America,
L Olbe, and
T Lind, and
E Carlsson, and
C Cederberg, and
H Helander, and
B Wallmark
June 1968,
The American journal of digestive diseases,
L Olbe, and
T Lind, and
E Carlsson, and
C Cederberg, and
H Helander, and
B Wallmark
February 1983,
Biochimica et biophysica acta,
L Olbe, and
T Lind, and
E Carlsson, and
C Cederberg, and
H Helander, and
B Wallmark
February 1974,
The Biochemical journal,
L Olbe, and
T Lind, and
E Carlsson, and
C Cederberg, and
H Helander, and
B Wallmark
September 2013,
Expert opinion on therapeutic patents,
L Olbe, and
T Lind, and
E Carlsson, and
C Cederberg, and
H Helander, and
B Wallmark
May 2015,
Expert opinion on therapeutic patents,
